Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $257.57, Implies 6% Upside

What happened

The average 12-month price target on Quest Diagnostics stock from 14 analysts rose from $255.57 to $257.57, with forecasts ranging from $235 to $279 per share. Based on the Oct. 26 closing price, this implies about 6% potential upside.

Confirmed

Global impact / market context

A higher average target means analysts on balance expect the lab-testing company's shares to be worth more over the next year. Investors who follow analyst ratings may treat this as a mildly positive signal, though the small size of the increase limits how much it changes the overall picture.

Analyst inference

The consensus rating stays at Buy across 20 analysts, split into 9 Buys, 11 Holds and no Sells. That mix suggests cautious optimism rather than strong conviction, and the spread from $235 to $279 shows analysts disagree meaningfully about where the stock will trade.

Analyst inference

What to watch

1. The updated average target of $257.57 comes from 14 analysts, with individual forecasts spanning $235 to $279 per share, so dispersion around the average remains notable. Confirmed
2. Watch whether more analysts move to Buy if future results support the higher target, which would shift the 9 Buy, 11 Hold, 0 Sell balance that defines the consensus. Proposed
3. If the stock trades near its Oct. 26 closing price, reaching the $257.57 average would require roughly 6% gain, so upgrades or earnings surprises would likely need to drive that move. Analyst inference

Evidence

• Original source link unavailable